In Quebec, most people who currently use one of the following original insulins: Lantus (Sanofi), Humalog (Lilly) or Novorapid (Novo Nordisk), are affected by the Transition to Biosimilars.
Indeed, on April 13 (Lantus and Humalog) and July 6 (Novorapid), the “Régie de l’Assurance Maladie du Québec” (RAMQ) will stop reimbursing these insulins. Instead, the RAMQ will reimburse Biosimilar insulins of its original insulins.
UPCOMING WEBINAR
MAY 27th – Diabetes Burnout
Learn more
MORE TOOL?
Comparative tables of insulin pumps or continuous glucose monitors, products to use in case of allergy or detachment (sensor, catheter), adjustment of insulin doses, factors influencing blood glucose, examples of snacks, ketones, etc.
Discover our PDFs
